Labiotech.eu

News and Trends 1 Nov 2022

Pancreatic cancer could be diagnosed years earlier

Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research from the U.K. shows. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates. In the largest study of its kind, researchers […]

November 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

Tetris Pharma launches hypoglycemia injector pen in Germany

Tetris Pharma Ltd, a subsidiary of biopharma company Arecor Therapeutics plc, has launched Ogluo (glucagon prefilled autoinjector pen) in Germany as a treatment for severe hypoglycemia in children and adults living with diabetes. Ogluo is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycemia. […]

November 1, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

Human Immunology Biosciences launches with $120M

Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced its launch with $120 million in financing. HI-Bio was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices. Few targeted therapies exist for the autoimmune, allergic […]

November 1, 2022 - 4 minutesmins - By Jim Cornall

More News! 31 Oct 2022

New drug application for chronic kidney disease sparks $35M milestone payment

A submission has been made for a new drug application by Japanese Kyowa Kirin Co. Ltd. for the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD). The company has submitted the application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor, which helps those with CKD on dialysis. Ardelyx, Inc. […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

First patient enrolled and dosed on expansion phase of cancer treatment trial

The first patient in an expansion phase of a trial looking at cancer drug Modi-1 has been enrolled and dosed. Scancell Holdings plc, the developer of immunotherapies for the treatment of cancer and infectious disease made the announcement today (October 31). The expansion phase is part of the monotherapy arms of the phase 1 clinical […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

Researchers develop efficient nanovaccine delivery system boosting cellular immunity

A research group has successfully developed a new nanovaccine delivery system, to strongly activate cellular immunity, using one-tenth of the amount of antigen that was previously required. Led by Eiji Yuba, an associate professor at the Graduate School of Engineering at Osaka Metropolitan University in Japan, the group has been developing been developing the […]

October 31, 2022 - 3 minutesmins - By Liza Laws

AMR antimicrobial resistance antibiotics

News and Trends 31 Oct 2022

Efflux pump inhibitor research may lead way to beating AMR

Researchers from SANKEN (The Institute of Scientific and Industrial Research), at Osaka University in Japan have provided new insights into the relationship between the position of “bulky” amino acids on bacterial proteins and the ability of bacteria to resist antibiotics. The medical profession is losing a race. Bacterial antibiotic resistance doesn’t only threaten the ability […]

October 31, 2022 - 3 minutesmins - By Jim Cornall

More News! 31 Oct 2022

Drug discovery company signs exclusive license to use university’s technology

A drug discovery and development company using deubiquitylase (DUB) modulators as therapeutics for areas of high unmet needs has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. Sheelagh Frame, is chief scientific officer, at Ubiquigent, the company that has signed the agreement. She said: “We are delighted to have […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

Replay Bio launches HSV gene therapy company to target retinal eye disease

Replay Bio has announced the launch of Eudora, an HSV (herpes simplex virus) gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Eudora’s co-founders Joe Glorioso, Mark Blumenkranz, David Schaffer, and Vinit Mahajan, are entrepreneurs who have worked in […]

October 31, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Scientists say RNA production inhibitors important in cancer research

A study by researchers at the Biomedical Institute of Seville (IBIS) and the University of Seville, in collaboration with the Danish Cancer Society, shows that inhibiting RNA synthesis after radiation therapy facilitates the death of tumor cells. The study was published in the journal Nature Communications. RNA has been shown to be essential for repairing […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Startup BioRaptor raises $3M to drive AI insights for scientists

BioRaptor has raised $3M in funding, which it says will allow it to put the power of AI-generated insights into the hands of every scientist. The round was led by lool Ventures and CPT Capital and was joined by FoodHack and other strategic angel investors. BioRaptor is building an operating system for biology research and […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

U.K. biopharma company PhoreMost Ltd. has entered into a multi-target collaboration with Arvinas, a company active in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. […]

October 31, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Pancreatic cancer could be diagnosed years earlier

Tetris Pharma launches hypoglycemia injector pen in Germany

Human Immunology Biosciences launches with $120M

New drug application for chronic kidney disease sparks $35M milestone payment

First patient enrolled and dosed on expansion phase of cancer treatment trial

Researchers develop efficient nanovaccine delivery system boosting cellular immunity

Efflux pump inhibitor research may lead way to beating AMR

Drug discovery company signs exclusive license to use university’s technology

Replay Bio launches HSV gene therapy company to target retinal eye disease

Scientists say RNA production inhibitors important in cancer research

Startup BioRaptor raises $3M to drive AI insights for scientists

PhoreMost and Arvinas to collaborate on drug discovery against multiple therapeutic targets

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!